Enveric Biosciences

Enveric Biosciences, founded with a mission to enhance patient lives, is a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders. Initially targeting the side effects of cancer treatments using natural compounds like cannabinoids, Enveric has evolved to leverage its unique discovery and development platform, The Psybrary™, to create a robust Intellectual Property portfolio of New Chemical Entities aimed at specific mental health conditions.

Notable figures affiliated with Enveric Biosciences include key industry experts and investors who have supported its innovative approach. The company has achieved significant milestones in expanding its IP portfolio and advancing its therapeutic candidates through rigorous testing. Enveric's impact lies in its commitment to addressing unmet medical needs, particularly in mental health, positioning itself as a leader in the biotech space dedicated to improving patient outcomes through cutting-edge science.